EUZ.DE
Eckert & Ziegler Strahlen- und Medizintechnik AG [EUZ.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EUZ.DE Stock Summary
Top 10 Correlated ETFs
EUZ.DE
Top 10 Correlated Stocks
EUZ.DE
In the News
EUZ.DE Financial details
Company Rating
Buy
Market Cap
715.95M
Income
26.3M
Revenue
246.09M
Book val./share
-
Cash/share
-
Dividend
0.5
Dividend %
1.15%
Employees
1.08K
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
34.56
Forward P/E
-
PEG
-11.33
P/S
3.75
P/B
4.06
P/C
-
P/FCF
82.16
Quick Ratio
1.86
Current Ratio
2.46
Debt / Equity
0.25
LT Debt / Equity
0.21
-
-
EPS (TTM)
0.98
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
6.63%
Revenue Q/Q
-5.62%
EPS Q/Q
-
-
-
-
-
SMA20
-7.89%
SMA50
-22.22%
SMA100
-10.26%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
12%
ROC
0.11%
Gross Margin
46%
Oper. Margin
17%
Profit Margin
11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
28.92-50.05
52W High
-33.6%
52W Low
+18.57%
RSI
30
Rel Volume
1.13
Avg Volume
56.8K
Volume
64.33K
Perf Week
-8.08%
Perf Month
-13.5%
Perf Quarter
-7.31%
Perf Half Y
-3.21%
-
-
-
-
Beta
1.094
-
-
Volatility
0.87%, 1.75%
Prev Close
-0.24%
Price
33.2
Change
-1.13%
EUZ.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.69 | 8.55 | 8.72 | 10.7 | 0 | |
| Net income per share | 1.07 | 1.03 | 1.67 | 1.41 | 0 | |
| Operating cash flow per share | 1.97 | 1.79 | 1.64 | 1.65 | 0 | |
| Free cash flow per share | 1.62 | 1.35 | 0.24 | 0.15 | 0 | |
| Cash per share | 3.81 | 4.3 | 4.59 | 3.97 | 0 | |
| Book value per share | 6.73 | 7.18 | 9.05 | 10.21 | 0 | |
| Tangible book value per share | 4.26 | 5.22 | 6.33 | 5.62 | 0 | |
| Share holders equity per share | 6.73 | 7.18 | 9.05 | 10.21 | 0 | |
| Interest debt per share | 1.02 | 1.05 | 1.36 | 2.47 | 0 | |
| Market cap | 971.16M | 925.73M | 1.96B | 965.48M | 0 | |
| Enterprise value | 912.13M | 858.65M | 1.89B | 932.37M | -11.69M | |
| P/E ratio | 44.11 | 43.49 | 56.67 | 32.98 | 0 | |
| Price to sales ratio | 5.44 | 5.26 | 10.84 | 4.34 | 0 | |
| POCF ratio | 24.02 | 25.16 | 57.8 | 28.15 | 0 | |
| PFCF ratio | 29.27 | 33.2 | 391.36 | 304.76 | 0 | |
| P/B Ratio | 7.03 | 6.26 | 10.44 | 4.55 | 0 | |
| PTB ratio | 7.03 | 6.26 | 10.44 | 4.55 | 0 | |
| EV to sales | 5.11 | 4.87 | 10.48 | 4.19 | -0.05 | |
| Enterprise value over EBITDA | 20.14 | 18.52 | 39.75 | 16.37 | -0.19 | |
| EV to operating cash flow | 22.56 | 23.34 | 55.83 | 27.18 | -0.25 | |
| EV to free cash flow | 27.49 | 30.8 | 378.02 | 294.31 | -0.55 | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.03 | 0 | |
| Free cash flow yield | 0.03 | 0.03 | 0 | 0 | 0 | |
| Debt to equity | 0.14 | 0.14 | 0.14 | 0.23 | 0.25 | |
| Debt to assets | 0.07 | 0.07 | 0.08 | 0.12 | 0.13 | |
| Net debt to EBITDA | -1.3 | -1.45 | -1.4 | -0.58 | -0.19 | |
| Current ratio | 3.36 | 3.52 | 2.94 | 2.78 | 2.79 | |
| Interest coverage | 28.88 | 29.54 | 38.52 | 23.94 | 11.77 | |
| Income quality | 1.8 | 1.59 | 0.98 | 1.15 | 1.55 | |
| Dividend Yield | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Payout ratio | 0.28 | 0.41 | 0.27 | 0.35 | 0.4 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.19 | 0.14 | 0.18 | 0.23 | 0.11 | |
| Capex to operating cash flow | -0.18 | -0.24 | -0.85 | -0.91 | -0.55 | |
| Capex to revenue | -0.04 | -0.05 | -0.16 | -0.14 | -0.11 | |
| Capex to depreciation | -0.65 | -0.81 | -3.01 | -2.84 | -1.96 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | -0.01 | 0 | |
| Graham number | 12.74 | 12.92 | 18.44 | 18 | 0 | |
| ROIC | 0.13 | 0.13 | 0.15 | 0.1 | 0.11 | |
| Return on tangible assets | 0.1 | 0.08 | 0.12 | 0.09 | 0.07 | |
| Graham Net | -0.26 | -0.65 | -0.63 | -2.79 | 0 | |
| Working capital | 103.04M | 123.72M | 117.15M | 117.7M | 149.97M | |
| Tangible asset value | 87.54M | 107.5M | 131.1M | 116.62M | 175.32M | |
| Net current asset value | 11.87M | 29.76M | 22.4M | -19.47M | 18.38M | |
| Invested capital | 0.14 | 0.14 | 0.14 | 0.23 | 0.25 | |
| Average receivables | 23.72M | 39.97M | 35.26M | 43.72M | 87.57M | |
| Average payables | 5.49M | 4.75M | 5.3M | 6.96M | 7.1M | |
| Average inventory | 29.99M | 32.4M | 35.47M | 44.49M | 45.77M | |
| Days sales outstanding | 97.01 | 67.36 | 76.9 | 81.16 | 186.47 | |
| Days payables outstanding | 17.91 | 20.45 | 22.78 | 26.36 | 16.51 | |
| Days of inventory on hand | 124.58 | 136.76 | 152.59 | 163.14 | 112.34 | |
| Receivables turnover | 3.76 | 5.42 | 4.75 | 4.5 | 1.96 | |
| Payables turnover | 20.39 | 17.85 | 16.02 | 13.85 | 22.11 | |
| Inventory turnover | 2.93 | 2.67 | 2.39 | 2.24 | 3.25 | |
| ROE | 0.16 | 0.14 | 0.18 | 0.14 | 0.12 | |
| Capex per share | -0.35 | -0.43 | -1.39 | -1.5 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.8 | 2.78 | 2.88 | 3.17 | 0 | |
| Net income per share | 0.29 | 0.23 | 0.3 | 0.45 | 0 | |
| Operating cash flow per share | 0.91 | 0.16 | 0.56 | 0.46 | 0 | |
| Free cash flow per share | 0.29 | -0.08 | 0.22 | 0.1 | 0 | |
| Cash per share | 3.97 | 3.84 | 3.71 | 4.25 | 0 | |
| Book value per share | 10.2 | 10.42 | 10.21 | 10.74 | 0 | |
| Tangible book value per share | 5.61 | 5.8 | 5.45 | 5.95 | 0 | |
| Share holders equity per share | 10.2 | 10.42 | 10.21 | 10.74 | 0 | |
| Interest debt per share | 2.41 | 2.58 | 2.69 | 3.1 | 0 | |
| Market cap | 966.99M | 870.98M | 759.64M | 672.96M | 0 | |
| Enterprise value | 933.87M | 843.87M | 737.48M | 648.12M | -11.69M | |
| P/E ratio | 40.57 | 45.9 | 30.79 | 17.94 | 0 | |
| Price to sales ratio | 16.6 | 15.03 | 12.65 | 10.21 | 0 | |
| POCF ratio | 51.26 | 261.95 | 64.81 | 70.22 | 0 | |
| PFCF ratio | 158.83 | -507.27 | 167.28 | 315.65 | 0 | |
| P/B Ratio | 4.56 | 4.02 | 3.58 | 3.01 | 0 | |
| PTB ratio | 4.56 | 4.02 | 3.58 | 3.01 | 0 | |
| EV to sales | 16.04 | 14.57 | 12.28 | 9.83 | -0.19 | |
| Enterprise value over EBITDA | 78.62 | 72.52 | 49.31 | 39.22 | -0.69 | |
| EV to operating cash flow | 49.5 | 253.8 | 62.92 | 67.63 | -0.51 | |
| EV to free cash flow | 153.4 | -491.48 | 162.4 | 304 | -0.72 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0 | 0 | |
| Debt to equity | 0.23 | 0.24 | 0.26 | 0.28 | 0.25 | |
| Debt to assets | 0.12 | 0.13 | 0.13 | 0.14 | 0.13 | |
| Net debt to EBITDA | -2.79 | -2.33 | -1.48 | -1.5 | -0.69 | |
| Current ratio | 2.78 | 2.73 | 2.43 | 2.46 | 2.79 | |
| Interest coverage | 15.26 | 10.59 | 10.78 | 13.77 | 11.43 | |
| Income quality | 3.14 | 0.7 | 1.87 | 1 | 2.3 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0 | 0 | 1.69 | 0 | 0 | |
| Sales general and administrative to revenue | -0.23 | 0.16 | 0.17 | 0.16 | -0.26 | |
| Research and developement to revenue | 0.07 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.23 | 0.23 | 0.23 | 0.23 | 0.11 | |
| Capex to operating cash flow | -0.68 | -1.52 | -0.61 | -0.78 | -0.29 | |
| Capex to revenue | -0.22 | -0.09 | -0.12 | -0.11 | -0.11 | |
| Capex to depreciation | -3.63 | -1.74 | -2.26 | -2.35 | -1.6 | |
| Stock based compensation to revenue | -0.03 | 0 | 0 | 0 | 0 | |
| Graham number | 8.11 | 7.31 | 8.25 | 10.43 | 0 | |
| ROIC | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Return on tangible assets | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Graham Net | -2.78 | -2.74 | -3.37 | -3.05 | 0 | |
| Working capital | 117.7M | 117.54M | 114.27M | 116.81M | 149.97M | |
| Tangible asset value | 116.62M | 120.67M | 113.37M | 123.74M | 175.32M | |
| Net current asset value | -19.47M | -16.32M | -25.15M | -21.61M | 18.38M | |
| Invested capital | 0.23 | 0.24 | 0.26 | 0.28 | 0.25 | |
| Average receivables | 47.63M | 54.81M | 63.06M | 63.41M | 93.31M | |
| Average payables | 6.22M | 7.3M | 5.96M | 5.26M | 5.36M | |
| Average inventory | 49.54M | 45.63M | 42.36M | 43.45M | 40.87M | |
| Days sales outstanding | 76.38 | 93.51 | 98.82 | 83.16 | 181.89 | |
| Days payables outstanding | 20.91 | 18.44 | 16.95 | 13.05 | 14.8 | |
| Days of inventory on hand | 129.43 | 116.93 | 134.84 | 112.55 | 100.69 | |
| Receivables turnover | 1.18 | 0.96 | 0.91 | 1.08 | 0.49 | |
| Payables turnover | 4.3 | 4.88 | 5.31 | 6.9 | 6.08 | |
| Inventory turnover | 0.7 | 0.77 | 0.67 | 0.8 | 0.89 | |
| ROE | 0.03 | 0.02 | 0.03 | 0.04 | 0.03 | |
| Capex per share | -0.61 | -0.24 | -0.34 | -0.36 | 0 |
EUZ.DE Frequently Asked Questions
What is Eckert & Ziegler Strahlen- und Medizintechnik AG stock symbol ?
Eckert & Ziegler Strahlen- und Medizintechnik AG is a DE stock and trading under the symbol EUZ.DE
What is Eckert & Ziegler Strahlen- und Medizintechnik AG stock quote today ?
Eckert & Ziegler Strahlen- und Medizintechnik AG stock price is $33.2 today.
Is Eckert & Ziegler Strahlen- und Medizintechnik AG stock public?
Yes, Eckert & Ziegler Strahlen- und Medizintechnik AG is a publicly traded company.
Company Profile
- Volume Average 56.8K
- Market Capitalization 715.95M
- Employee 1.08K
- CEO Dr. Harald Hasselmann
- Headquarters Berlin,DE
- IPO Date 1999-05-26
-
Website
https://www.ezag.com 
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
